Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 1.18B |
| Revenue (ttm) | 220.36M |
| Net Income (ttm) | -22.55M |
| Shares Out | 143.18M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | 22.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,250,145 |
| Open | 8.07 |
| Previous Close | 8.13 |
| Day's Range | 7.91 - 8.26 |
| 52-Week Range | 4.71 - 9.74 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 10.33 (+25.36%) |
| Earnings Date | Nov 7, 2024 |
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. [Read more]
Financial Performance
In 2023, Aurinia Pharmaceuticals's revenue was $175.51 million, an increase of 30.95% compared to the previous year's $134.03 million. Losses were -$78.02 million, -27.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 25.36% from the latest price.
News
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual Ame...
Aurinia to Participate in Jefferies London Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference.
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impres...
Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf ...
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth.
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months ended...
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024.
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024.
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA ANNOUNCES JAPAN APPROVAL OF LUPKYNIS® (VOCLOSPORIN) TO TREAT LUPUS NEPHRITIS.
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong mome...
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. T...
Aurinia Pharmaceuticals: This Recovery Can Continue
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is develop...
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference.
Aurinia Announces Board Restructuring
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Board Restructuring.
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial.
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference.
Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board
GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the below open le...
Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - ...
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results.
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024.
ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM
SEOUL, South Korea--(BUSINESS WIRE)--ILJIN SNT Co., Ltd. ("ILJIN"), one of the largest shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) ("Aurinia" or the "Company"), today issued an open letter ...
Aurinia Pharmaceuticals Appears Undervalued
Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by layin...
Aurinia to Participate in Upcoming Investor Healthcare Conferences
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.
Aurinia Announces 2024 Annual General Meeting Results
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces 2024 Annual General Meeting Results.